Schizophrenia Treatment, Brexpiprazole, Seen to Ease Agitation in Alzheimer’s Patients in Phase 3 Trial

Schizophrenia Treatment, Brexpiprazole, Seen to Ease Agitation in Alzheimer’s Patients in Phase 3 Trial
The schizophrenia medication Rexulti (brexpiprazole) reduced agitation in patients with Alzheimer’s disease, newly released data from two Phase 3 clinical trials of the drug show. The studies highlight that efforts are ongoing to target symptoms — other than dementia itself — to improve the quality of life of Alzheimer’s patients and their loved ones. The

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *